← Back to Screener
ClearPoint Neuro, Inc. Common Stock (CLPT)
Price$10.50
Favorite Metrics
Price vs S&P 500 (26W)-68.65%
Price vs S&P 500 (4W)3.08%
Market Capitalization$310.28M
All Metrics
Book Value / Share (Quarterly)$0.95
P/TBV (Annual)28.87x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)21.62%
Cash Flow / Share (Quarterly)$-0.83
Price vs S&P 500 (YTD)-26.18%
Gross Margin (TTM)61.38%
Net Profit Margin (TTM)-69.08%
EPS (TTM)$-0.90
10-Day Avg Trading Volume0.56M
EPS Excl Extra (TTM)$-0.90
Revenue Growth (5Y)23.57%
EPS (Annual)$-0.90
ROI (Annual)-33.13%
Gross Margin (Annual)61.38%
Net Profit Margin (5Y Avg)-77.99%
Cash / Share (Quarterly)$1.56
Revenue Growth QoQ (YoY)33.96%
ROA (Last FY)-26.13%
Revenue Growth TTM (YoY)17.78%
EBITD / Share (TTM)$-0.83
ROE (5Y Avg)-68.81%
Operating Margin (TTM)-65.36%
Cash Flow / Share (Annual)$-0.83
P/B Ratio11.07x
P/B Ratio (Quarterly)14.52x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)8.48x
Net Interest Coverage (TTM)-20.69x
ROA (TTM)-40.69%
EPS Incl Extra (Annual)$-0.90
Current Ratio (Annual)5.91x
Quick Ratio (Quarterly)4.94x
3-Month Avg Trading Volume0.77M
52-Week Price Return-9.36%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.48
P/S Ratio (Annual)8.39x
Asset Turnover (Annual)0.38x
52-Week High$30.10
Operating Margin (5Y Avg)-76.68%
EPS Excl Extra (Annual)$-0.90
CapEx CAGR (5Y)1.69%
Tangible BV CAGR (5Y)47.34%
26-Week Price Return-64.66%
Quick Ratio (Annual)4.94x
13-Week Price Return-33.16%
Total Debt / Equity (Annual)1.75x
Current Ratio (Quarterly)5.91x
Enterprise Value$313.438
Revenue / Share Growth (5Y)10.03%
Asset Turnover (TTM)0.59x
Book Value / Share Growth (5Y)46.87%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.88x
Pretax Margin (Annual)-68.93%
Cash / Share (Annual)$1.56
3-Month Return Std Dev97.54%
Gross Margin (5Y Avg)62.85%
Net Income / Employee (TTM)$-0
ROE (Last FY)-91.15%
Net Interest Coverage (Annual)-13.69x
EPS Basic Excl Extra (Annual)$-0.90
Receivables Turnover (TTM)6.17x
Total Debt / Equity (Quarterly)1.75x
EPS Incl Extra (TTM)$-0.90
Receivables Turnover (Annual)6.17x
ROI (TTM)-53.56%
P/S Ratio (TTM)8.39x
Pretax Margin (5Y Avg)-77.95%
Revenue / Share (Annual)$1.31
Tangible BV / Share (Annual)$0.48
Price vs S&P 500 (52W)-39.19%
Year-to-Date Return-23.54%
5-Day Price Return16.74%
EPS Normalized (Annual)$-0.90
ROA (5Y Avg)-35.55%
Net Profit Margin (Annual)-69.08%
Month-to-Date Return14.95%
Cash Flow / Share (TTM)$-0.87
EBITD / Share (Annual)$-0.86
Operating Margin (Annual)-65.36%
LT Debt / Equity (Annual)1.75x
ROI (5Y Avg)-47.67%
LT Debt / Equity (Quarterly)1.75x
EPS Basic Excl Extra (TTM)$-0.90
P/TBV (Quarterly)28.87x
P/B Ratio (Annual)14.52x
Inventory Turnover (TTM)1.88x
Pretax Margin (TTM)-68.93%
Book Value / Share (Annual)$0.95
Price vs S&P 500 (13W)-33.85%
Beta1.22x
P/FCF (Annual)49.17x
Revenue / Share (TTM)$1.28
ROE (TTM)-122.17%
52-Week Low$8.27
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
CLPTClearPoint Neuro, Inc. Common Stock | 8.39x | 23.57% | 61.38% | -65.36% | $10.50 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
ClearPoint Neuro develops and commercializes minimally invasive surgical platforms for brain and cardiac procedures guided by real-time MRI imaging. The company's flagship ClearPoint system is currently in commercial use and addresses a significant market need for precise, image-guided neurosurgery. Revenue is generated through system sales, services, disposables, and software solutions.